Journal Club Review: Upadacitinib Safety & Efficacy in Pediatric JIA (Phase-1 Interim Data)

Join Ingrid Pan, PharmD, Pediatric Clinical Pharmacist at Children’s Hospital Colorado, as she reviews the latest findings from the Phase 1 trial of Upadacitinib (Rinvoq) in treating pediatric polyarticular course juvenile idiopathic arthritis (JIA). This interim analysis, published in Annals of the Rheumatic Diseases, explores the potential of JAK1-selective inhibition in pediatric rheumatology.This open-label, three-part Phase 1 study evaluated pharmacokinetics, safety, and efficacy in patients aged 2-18 across North America, Europe, and Asia. Results demonstrated promising clinical responses, with an ACR 30 response rate of 92% at Week 12, ACR 50 response of 90%, and ACR 70 response of 69%. Safety data indicated mild-to-moderate adverse events, including upper respiratory tract infections, COVID-19 infections, gastroenteritis, neutropenia, and CPK elevations.With FDA approval and orphan drug designation granted in June 2024, Upadacitinib represents a potential new treatment option for pediatric JIA, offering targeted JAK1 inhibition to improve disease outcomes.For more expert insights into pediatric rheumatology, JIA treatments, and clinical trial data, visit RhAPP.org or explore the RhAPP ACE App.